AN2 Therapeutics, Inc.
ANTX
$1.25
-$0.04-3.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.61% | -7.12% | 21.81% | -10.19% | 4.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.25% | -35.25% | -4.34% | 14.07% | 50.81% |
| Operating Income | 54.25% | 35.25% | 4.34% | -14.07% | -50.81% |
| Income Before Tax | 55.49% | 23.70% | 8.66% | -8.44% | -42.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.49% | 23.70% | 8.66% | -8.44% | -42.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.49% | 23.70% | 8.66% | -8.44% | -42.70% |
| EBIT | 54.25% | 35.25% | 4.34% | -14.07% | -50.81% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 55.71% | 34.43% | 40.29% | 29.36% | 7.13% |
| Normalized Basic EPS | 55.66% | 45.97% | 40.29% | 29.37% | 7.11% |
| EPS Diluted | 55.71% | 34.43% | 40.29% | 29.36% | 7.13% |
| Normalized Diluted EPS | 55.66% | 45.97% | 40.29% | 29.37% | 7.11% |
| Average Basic Shares Outstanding | 0.50% | 16.36% | 52.97% | 53.53% | 53.65% |
| Average Diluted Shares Outstanding | 0.50% | 16.36% | 52.97% | 53.53% | 53.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |